Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark Pharmaceuticals has said that its drug candidate for rheumatoid arthritis, inflammation and multiple sclerosis, GRC 4039 has entered Phase I trials.
Subscribe to our email newsletter
The trial was initiated after the approval from the Medicines and Healthcare Products Regulatory Agency [MHRA] in the UK. The company intends to develop GRC 4039, a PDE 4 inhibitor, in rheumatoid arthritis (RA) as the primary indication. Glenmark expects to complete Phase I trials for GRC 4039 by October 2008 and initiate Phase II by January 2009.
Glenn Saldanha, managing director & CEO of Glenmark, said: “We are happy to take GRC 4039 forward into Phase I trials. This is Glenmark’s fourth molecule to enter the clinics from our pipeline of eight NCEs and NBEs, and demonstrates our steady progress in the drug discovery space.”